Following the 2022 mpox outbreak, dozens of cases occurred in young children within the U.S., and thousands have occurred internationally, where the Clade I virus has disproportionately affected young children in the Democratic Republic of Congo and surrounding areas.This is particularly concerning as increased severity of disease, mortality, and rates of hospitalization have been reported in this population. Given these poor outcomes, there is a critical need for therapies in pediatric-friendly formulations.
William Fischer, II, MD, Director of Emerging Pathogens for the Institute for Global Health and Infectious Diseases is an expert in severe emerging viral pathogens, including Ebola virus disease, Lassa fever, and SARS-CoV-2. In the Journal of Pediatric Infectious Diseases Society, Dr. Fischer evaluated the dose accuracy and recovery of Tecovirimat capsule contents when mixed in water.